BioSpace

Entzun zure aplikazioan

• Apple Podcasts
• Pocket Casts
• Castro
• Podcast Index
• RSS

Atalak

282 atal

1. Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November duela 4 ordu 23:50
2. Beyond the needle: The future of intratumoral therapy duela 1 aste 21:02
3. Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review duela 1 aste 23:00
4. Stability, speed and strategy: Inside Australia’s early‑stage edge duela 2 aste 21:19
5. Data leak kickstarts ESMO, BMS reports autoimmune CAR T death, pharma M&A outpaces 2025 duela 2 aste 23:34
6. Why investors are taking another look at kidney disease duela 3 aste 18:26
7. Disc’s redemption, China’s rise, Veradermics’ validation, ESMO’s headliners duela 3 aste 17:49
8. Bonus: Q3 2026 Job Market Update duela 3 aste 16:20
9. The decisions behind scientific progress duela 1 hilabete 10:52
10. J&J’s disappointing Q3, RevMed’s subgroup data, BMS’ ‘mixed’ results, Caribou’s cutback duela 1 hilabete 19:48
11. Beyond equity: Why venture debt is reshaping European biotech duela 1 hilabete 22:35
12. Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more duela 1 hilabete 24:18
13. The race for access: How the FAIR Act could reclaim U.S. biotech leadership duela 1 hilabete 20:28
14. AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll duela 1 hilabete 20:09
15. How radioligand therapy is rewriting cancer care duela 2 hilabete 15:38
16. Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz duela 2 hilabete 21:21
17. When vision fades: Rethinking wet AMD and the durability gap duela 2 hilabete 21:35
18. FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival duela 2 hilabete 22:11
19. The supply chain fault lines of modern pharma duela 2 hilabete 36:20
20. Novo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease duela 2 hilabete 20:19
21. Breaking borders: Building biotech scale in Benelux duela 2 hilabete 18:34
22. Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals duela 2 hilabete 20:23
23. Fragile X at a turning point: Breaking through the clinical bottleneck duela 3 hilabete 19:23
24. Capricor’s DMD therapy still alive, Merck/Moderna’s cancer vax shines, FDA’s future revealed duela 3 hilabete 23:27
25. Rewriting the rules of CMV prevention duela 3 hilabete 19:39
26. Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more duela 3 hilabete 19:08
27. The Italian inflection point: Clinical strength, culture and capital duela 3 hilabete 18:54
28. Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight duela 3 hilabete 19:01
29. Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms duela 3 hilabete 23:14
30. The next treatment-resistant depression paradigm duela 3 hilabete 20:18
31. Life after the lead asset: Advancing an early-stage pipeline duela 3 hilabete 24:01
32. Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more duela 4 hilabete 17:10
33. Nordic biotech’s next act: From fragmentation to global force duela 4 hilabete 20:18
34. Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2 duela 4 hilabete 21:20
35. The future of pain relief: Exploring opioid alternatives duela 4 hilabete 19:11
36. Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup duela 4 hilabete 21:22
37. Bonus: Q2 2026 Job Market Update duela 4 hilabete 9:01
38. From sequence to scale: Gene editing’s new era in biologics manufacturing duela 4 hilabete 20:41
39. Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil duela 4 hilabete 17:04
40. Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water duela 4 hilabete 22:54
41. The Golden Triangle and the gaps: Rethinking UK biotech duela 5 hilabete 19:37
42. AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more duela 5 hilabete 21:36
43. From fragile skin to living medicine: Lessons from RDEB duela 5 hilabete 21:43
44. Moderna’s FDA adcomm, IPO mania, biopharma layoffs, more duela 5 hilabete 25:33
45. Portugal, Spain and the new biotech frontier duela 5 hilabete 20:33
46. Lilly tees off with Novo at ADA, GSK’s $10.6B deal, FDA reform continues in Makary’s absence duela 5 hilabete 25:02
47. Rethinking hair loss treatment duela 5 hilabete 21:45
48. ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck duela 5 hilabete 27:04
49. France’s biotech ecosystem: science, capital and scale duela 6 hilabete 21:00
50. Lilly wheels and deals, Moderna gets boost on hantavirus scare, ASCO excitement builds duela 6 hilabete 24:32